Fig. 2

PFKFB4 is differentially expressed in ccRCC. A) Reproduced from the Cancer Genome Atlas (TCGA) clear-cell renal cell carcinoma (KIRC) dataset, shown was expression of PFKFB4 in paired normal and cancerous tissue of ccRCC, paired Student’s t test; B) Reproduced from 2 GEO datasets, shown were differential expressions of PFKFB4 in normal and ccRCC tissue, unpaired Mann-Whitney tests; C) Reproduced from International Cancer Genome Consortium (IGCG) ccRCC dataset, shown was differential expression of PFKFB4 in normal and ccRCC tissue, unpaired Mann-Whitney test; D) Kaplan-Meier plot of overall survival in TCGA-KIRC cohort grouped by higher and lower PFKFB4 expression, Log-rank test; E) The time-dependent receiver operating characteristic (ROC) analysis for the tumor grades, pathological stages, and the PFKFB4 levels in the TCGA-KIRC cohort; F) Multivariate analyses of TCGA-KIRC cohort with bars representing 95 % CIs; G) Retrieved from mRNA microarray data, shown was expression of PFKFB4 in 19 paired ccRCC samples (left panel) and representative immunohistochemical staining of PFKFB4 in 5 paired samples zoomed out to demonstrate expression trends (right panel), paired Student’s t-test. H) Efficacy of PFKFB4 knockdown (KD) in 2 ccRCC cell lines using 2 shRNAs (KD1 and KD2) and scrambled negative control (NC), measured by both quantitative PCR and western blotting. (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001)